Glia cell number modulates sensitivity to MPTP in mice

GLIA

Volumn 52, Issue 2, 2005, Pages 144-152

  Smeyne, Michelle ^a   Jiao, Yun ^a   Shepherd, Kennie R ^a   Smeyne, Richard J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Astrocytes; Microglia; Oxidative stress; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL COUNT; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GLIA; GLIA CELL; MOUSE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIMETABOLITES; BROMODEOXYURIDINE; CELL COUNT; CELLS, CULTURED; DOPAMINE AGENTS; DRUG RESISTANCE; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; NEUROGLIA; PARKINSON DISEASE, SECONDARY; S100 PROTEINS; SUBSTANTIA NIGRA;

EID: 27844536914     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/glia.20233     Document Type: Article

References (76)

1. Adami C, Sorci G, Blasi E, Agneletti AL, Bistoni F, Donato R. 2001. S-100B expression in and effects on microglia. Glia 33:131-142.
2. Adams JD Jr, Chang ML, Klaidman L. 2001. Parkinson's disease-redox mechanisms. Curr Med Chem 8:809-814.
3. Ahlgren-Beckendorf JA, Reising AM, Schander MA, Herdler JW, Johnson JA. 1999. Coordinate regulation of NAD(P)H:quinone oxidoreductase and glutathione-S-transferases in primary cultures of rat neurons and glia: role of the antioxidant/electrophile responsive element. Glia 25:131-142.
4. Beal MF. 2003. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann NY Acad Sci 991:120-131.
5. Beal MF. 2004. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr 36:381-386.
6. Betarbet R, Sherer TB, Greenamyre JT. 2002. Animal models of Parkinson's disease. BioEssays 24:308-318.
7. Chanas SA, Jiang Q, McMahon M, McWalter GK, McLellan LI, Elcombe CR, Henderson CJ, Wolf CR, Moffat GJ, Itoh K, Yamamoto M, Hayes JD. 2002. Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. Biochem J 365(Pt 2):405-416.
8. Cheng FC, Ni DR, Wu MC, Kuo JS, Chia LG. 1998. Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice. Neurosci Lett 252:87-90.
9. Choi HJ, Kim SW, Lee SY, Hwang O. 2003. Dopamine-dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson's disease. J Neurochem 86:143-152.
10. Cook R, Lu L, Gu J, Williams RW, Smeyne RJ. 2003. Identification of a single QTL, Mptp1, for susceptibility to MPTP-induced substantia nigra pars compacta neuron loss in mice. Mol Brain Res 110:279-288.
11. + binds to neuromelanin. Science 231:987-989.
12. Date I, Aoi M, Tomita S, Collins F, Ohmoto T. 1998. GDNF administration induces recovery of the nigrostriatal dopaminergic system both in young and aged parkinsonian mice. NeuroReport 9:2365-2369.
13. Dringen R. 2000. Metabolism and functions of glutathione in brain. Prog Neurobiol 62:649-671.
14. Dringen R, Hirrlinger J. 2003. Glutathione pathways in the brain. Biol Chem 384:505-516.
15. Dringen R, Pfeiffer B, Hamprecht B. 1999. Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci 19:562-569.
16. Drukarch B, Schepens E, Stoof JC, Langeveld CH, Van Muiswinkel FL. 1998. Astrocyte-enhanced neuronal survival is mediated by scavenging of extracellular reactive oxygen species. Free Rad Biol Med 25:217-220.
17. Ferger B, Leng A, Mura A, Hengerer B, Feldon J. 2004. Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J Neurochem 89:822-833.
18. + kinetics and MPTP-induced nigrostriatal dopamine depletions. J Pharmacol Exp Ther 283:100-107.
19. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. 1994. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 91:5104-5108.
20. Gayle DA, Ling Z, Tong C, Landers T, Lipton JW, Carvey PM. 2002. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Dev Brain Res 133:27-35.
21. German DC, Nelson EL, Liang CL, Speciale SG, Sinton CM, Sonsalla PK. 1996. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration 5:299-312.
22. Gong L, Wyatt RJ, Baker I, Masserano JM. 1999. Brain-derived and glial cell line-derived neurotrophic factors protect a catecholaminergic cell line from dopamine-induced cell death. Neurosci Lett 263:153-156.
23. Hadjiconstantinou M, Fitkin JG, Dalia A, Neff NH. 1991. Epidermal growth factor enhances striatal dopaminergic parameters in the 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mouse. J Neurochem 57:479-482.
24. Hamre K, Tharp R, Poon K, Xiong X, Smeyne RJ. 1999. Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res 828:91-103.
25. Hastings TG. 1995. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 64:919-924.
26. Hatakeyama S, Hayasaki Y, Masuda M, Kazusaka A, Fujita S. 1996. Mechanism for mouse strain differences in the protective effect of Sudan III against the in vivo genotoxicity of 7,12-dimethylbenz[a]anthracene. Toxicol Lett 89:231-239.
27. Heaton MB, Paiva M, Madorsky I, Mayer J, Moore DB. 2003. Effects of ethanol on neurotrophic factors, apoptosis-related proteins, endogenous antioxidants, and reactive oxygen species in neonatal striatum: relationship to periods of vulnerability. Brain Res Dev Brain Res 140:237-252.
28. Hirrlinger J, Schulz JB, Dringen R. 2002. Effects of dopamine on the glutathione metabolism of cultured astroglial cells: implications for Parkinson's disease. J Neurochem 82:458-467.
29. Hirsch EC, Faucheux BA. 1998. Iron metabolism and Parkinson's disease. Mov Disord 13(suppl 1):39-45.
30. Hirsch EC, Graybiel AM, Agid Y. 1989. Selective vulnerability of pigmented dopaminergic neurons in Parkinson's disease. Acta Neurol Scand 126(suppl):19-22.
31. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC. 1996. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72:355-363.
32. Jackson-Lewis V, Smeyne RJ. 2004. From man to mouse: the MPTP model of Parkinson's disease. In: LeDoux M, editor. Animal models of movement disorders: Amsterdam: Elsevier, p 151-162.
33. Jellinger KA. 1999. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14:115-140.
34. +-ATPase activity in crude synaptosomal- mitochondrial fraction from rat brain. Free Radic Res 37:597-601.
35. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS. 2000. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 20:6309-6316.
36. + toxicity and oxidative stress in neonatal animals. Brain Res 713:178-185.
37. Kraft AD, Johnson DA, Johnson JA. 2004. Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tertbutylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci 24:1101-1112.
38. Kranich O, Dringen R, Sandberg M, Hamprecht B. 1998. Utilization of cysteine and cysteine precursors for the synthesis of glutathione in astroglial cultures: preference for cystine. Glia 22:11-18.
39. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. 1999. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46:598-605.
40. LaVoie MJ, Hastings TG. 1999. Peroxynitrite- and nitrite-induced oxidation of dopamine: implications for nitric oxide in dopaminergic cell loss. J Neurochem 73:2546-2554.
41. Lee JM, Johnson JA. 2004. An important role of Nrf2-ARE pathway in the cellular defense mechanism. J Biochem Mol Biol 37:139-143.
42. Liu B, Gao HM, Hong JS. 2003. Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect 111:1065-1073.
43. Liu B, Hong JS. 2003. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 304:1-7.
44. Mann DM, Yates PO. 1983. Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech Aging Dev 21:193-203.
45. McGeer PL, McGeer EG. 1998. Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimers Dis Assoc Dis 12(suppl 2):S1-6.
46. McGeer PL, McGeer EG. 2004. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 10(suppl 1):S3-7.
47. Minghetti L. 2004. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63:901-910.
48. Murphy TH, Yu J, Ng R, Johnson DA, Shen H, Honey CR, Johnson JA. 2001. Preferential expression of antioxidant response element mediated gene expression in astrocytes. J Neurochem 76:1670-1678.
49. Nakajima K, Hida H, Shimano Y, Fujimoto I, Hashitani T, Kumazaki M, Sakurai T, Nishino H. 2001. GDNF is a major component of trophic activity in DA-depleted striatum for survival and neurite extension of DAergic neurons. Brain Res 916:76-84.
50. Nathan C, Xie QW. 1994. Regulation of biosynthesis of nitric oxide. J Biol Chem 269:13725-13728.
51. Olanow CW, Tatton WG. 1999. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22:123-144.
52. Otto D, Unsicker K. 1994. FGF-2 in the MPTP model of Parkinson's disease: effects on astroglial cells. Glia 11:47-56.
53. Petersen AA, Larsen KE, Behr GG, Romero N, Przedborski S, Brundin P, Sulzer D. 2001. Brain-derived neurotrophic factor inhibits apoptosis and dopamine-induced free radical production in striatal neurons but does not prevent cell death. Brain Res Bull 56:331-335.
54. Radi R, Cassina A, Hodara R, Quijano C, Castro L. 2002. Peroxynitrite reactions and formation in mitochondria. Free Radic Biol Med 33:1451-1464.
55. +. Neurosci Lett 75:323-328.
56. Rice-Evans CA. 1994. Formation of free radicals and mechanisms of action in normal biochemical processes and pathological states. In: Rice-Evans CA, Burdon RH, editors. Free radical damage and its control. Amsterdam: Elsevier, p 131-153.
57. Riedl AG, Watts PM, Brown CT, Jenner P. 1999. P450 and heme oxygenase enzymes in the basal ganglia and their roles in Parkinson's disease. Adv Neurol 80:271-286.
58. Rothermundt M, Peters M, Prehn JH, Arolt V. 2003. S-100B in brain damage and neurodegeneration. Microsc Res Tech 60:614-632.
59. Rushmore TH, Morton MR, Pickett CB. 1991. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem 266:11632-11639.
60. Sagara JI, Miura K, Bannai S. 1993. Maintenance of neuronal glutathione by glial cells. J Neurochem 61:1672-1676.
61. Salinas AE, Wong MG. 1999. Glutathione S-transferases-a review. Curr Med Chem 6:279-309.
62. Schaar DG, Sieber BA, Dreyfus CF, Black IB. 1993. Regional and cell-specific expression of GDNF in rat brain. Exp Neurol 124:368-371.
63. Schaar DG, Sieber BA, Sherwood AC, Dean D, Mendoza G, Ramakrishnan L, Dreyfus CF, Black IB. 1994. Multiple astrocyte transcripts encode nigral trophic factors in rat and human. Exp Neurol 130:387-393.
64. Schabitz WR, Sommer C, Zoder W, Kiessling M, Schwaninger M, Schwab S. 2000. Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Stroke 31:2212-2217.
65. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD. 1994. Glutathione-related enzymes in brain in Parkinson's disease. Annals of Neurology 36:356-361.
66. Skaper SD, Floreani M, Negro A, Facci L, Giusti P. 1998. Neurotrophins rescue cerebellar granule neurons from oxidative stress-mediated apoptotic death: selective involvement of phosphatidylinositol 3-kinase and the mitogen-activated protein kinase pathway. J Neurochem 70:1859-1868.
67. Slivka A, Cohen G. 1985. Hydroxyl radical attack on dopamine. J Biol Chem 260:15466-15472.
68. +-induced Parkinsonism is determined by glia. Glia 74:73-80.
69. Smeyne M, Smeyne RJ. 2002. Method for culturing postnatal substantia nigra as an in vitro model of experimental Parkinson's disease. Brain Res Prot 9:105-111.
70. Spina MB, Squinto SP, Miller J, Lindsay RM, Hyman C. 1992. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J Neurochem 59:99-106.
71. Teismann P, Tieu K, Cohen O, Choi DK, Wu du C, Marks D, Vila M, Jackson-Lewis V, Przedborski S. 2003. Pathogenic role of glial cells in Parkinson's disease. Mov Disord 18:121-129.
72. Tsukahara T, Takeda M, Shimohama S, Ohara O, Hashimoto N. 1995. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced parkinsonism in monkeys. Neurosurgery 37:733-739.
73. Wang XF, Cynader MS. 2000. Astrocytes provide cysteine to neurons by releasing glutathione. J Neurochem 74:1434-1442.
74. West MJ, Slomianka L, Gundersen HJ. 1991. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231:482-497.
75. Wullner U, Klockgether T. 2003. Inflammation in Parkinson's disease. J Neurol 250(suppl 1):I35-38.
76. Yoshida M. 2001. Intermediate filament proteins define different glial subpopulations. J Neurosci Res 63:284-289.